Trading Signals: LGND Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Ligand Pharmaceuticals Inc)
| LGND latest price $108.5900 (-2.1%) ($107.2900 - $111.3100) on Wed. Aug. 17, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.14% (three month average) | RSI | 15 | Latest Price | $108.5900(-2.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | LGND declines -0.8% a day on average for past five trading days. | Weekly Trend | LGND declines -8.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support LGND advance at 0% a week (0% probability) IBB(59%) IWO(56%) XBI(56%) IWC(52%) IWM(52%) | Factors Impacting LGND price | LGND will decline at least -1.07% in a week (0% probabilities). VIXM(-15%) TLT(-15%) UUP(-8%) IPO(-4%) GDXJ(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.07% (StdDev 2.14%) | Hourly BBV | 0 () | Intraday Trend | -2.4% | | | |
|
Resistance Level | $124.74 | 5 Day Moving Average | $112.33(-3.33%) | 10 Day Moving Average | $116.02(-6.4%) | 20 Day Moving Average | $124.74(-12.95%) | To recent high | -21.6% | To recent low | 0% | Market Cap | $1.745b | | | | Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA. |